Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release

Abstract

Chk1 is a key regulator of the S and G2/M checkpoints and is activated following DNA damage by agents such as the topoisomerase I inhibitor camptothecin (CPT). It has been proposed that Chk1 inhibitors used in combination with such a DNA damaging agent to treat tumors would potentiate cytotoxicity and increase the therapeutic index, particularly in tumors lacking functional p53. The aim of this study was to determine whether gene expression analysis could be used to inform lead optimization of a novel series of Chk1 inhibitors. The candidate small-molecule Chk1 inhibitors were used in combination with CPT to identify potential markers of functional Chk1 inhibition, as well as resulting cell cycle progression, using cDNA-based microarrays. Differential expression of several of these putative marker genes was further validated by RT-PCR for use as a medium-throughput assay. In the presence of DNA damage, Chk1 inhibitors altered CPT-dependent effects on the expression of cell cycle and DNA repair genes in a manner consistent with a Chk1-specific mechanism of action. Furthermore, differential expression of selected marker genes, cyclin E2, EGR1, and DDIT3, was dose dependent for Chk1 inhibition. RT-PCR results for these genes following treatment with a panel of Chk1 inhibitors showed a strong correlation between marker gene response and the ability of each compound to abrogate cell cycle arrest in situ following CPT-induced DNA damage. These results demonstrate the utility of global expression analysis to identify surrogate markers, providing an alternative method for rapid compound characterization to support advancement decisions in early drug discovery.

Keywords

microarray Chk1 surrogate marker cell cycle RT-PCR

References

Iliakis G , Wang Y , Guan J , Wang H : DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003;22: 5834-5847.

Xiao Z , Chen Z , Gunasekera AH , Sowin TJ , Rosenberg SH , Fesik S , et al : Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003;278: 21767-21773.

Zhao H , Watkins JL , Piwnica-Worms H : Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002;99: 14795-14800.

Koniaras K , Cuddihy AR , Christopoulos H , Hagg A , O’Connell MJ : Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001;20: 7453-7463.

Powell SN , DeFrank JS , Connell P , Eogan M , Preffer F , Dombkowski D , et al : Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55: 1643-1648.

Liu LF , Desai SD , Li T-K , Mao Y , Sun M , Sim S-P : Mechanism of action of camptothecin. Ann N Y Acad Sci 2000;922: 1-10.

Jones CB , Clements MK , Wasi S , Daoud SS : Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. Cancer Chemother Pharmacol 1992;40: 475-483.

Motwani M , Jung C , Sirotnak FM , She Y , Shah MA , Gonen M , et al : Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7: 4209-4219.

Graves PR , Yu L , Schwarz JK , Gales J , Sausville EA , O’Connor PM , et al : The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275: 5600-5605.

10.

Kohn EA , Ruth ND , Brown MK , Livingstone M , Eastman A : Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystau-rosporine and the kinetics of Cdc25C activation. J Biol Chem 2002;277: 26553-26564.

11.

Jones CB , Clements MK , Wasi S , Daoud SS : Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G2 arrest. Cancer Chemother Pharmacol 2000;45: 252-258.

12.

Mack PC , Gandara DR , Lau AH , Lara PN Jr , Edelman MJ , Gumerlock PH : Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol 2003;51: 337-348.

13.

Patel V , Lahusen T , Leethanakul C , Igishi T , Kremer M , Quintanilla-Martinez L , et al : Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27 (KIP1). Clin Cancer Res 2002;8: 3549-3560.

14.

Koh J , Kubota T , Migita T , Abe S , Hashimoto M , Hosoda Y , et al : UCN- 01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction. Breast Cancer 2002;9: 50-54.

15.

Abe S , Kubota T , Otani Y , Furukawa T , Watanabe M , Kumai K , et al : UCN-01 (7-hydroxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. Jpn J Cancer Res 2001;92: 537-545.

16.

Busby EC , Leistritz DF , Abraham RT , Karnitz LM , Sarkaria JN : The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60: 2108-2112.

17.

Yu Q , La Rose J , Zhang H , Takemura H , Kohn KW , Pommier Y : UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002;62: 5743-5748.

18.

Senderowicz AM : Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 2000;19: 6600-6606.

19.

Wang Q , Worland PJ , Clark JL , Carlson BA , Sausville EA : Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Diff 1995;6: 927-936.

20.

Togashi A , Katagiri T , Ashida S , Fujioka T , Maruyama O , Wakumoto Y , et al : Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 2005;65: 4817-4826.

21.

Barrier A , Lemoine A , Boelle P-Y , Tse C , Brault D , Chiappini F , et al : Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005;24: 6155-6164.

22.

Sawada H , Takami K , Asahi S : A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005;83: 282-292.

23.

Allison DB , Cui X , Page GP , Sabripour M : Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genetics 2006;7: 55-65.

24.

Bevington PR , Robinson DK : Data Reduction and Error Analysis for the Physical Sciences. San Francisco, CA: WCB/McGraw-Hill, 1992.

25.

Khanna KK , Jackson SP : DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genetics 2001;27: 247-254.

26.

Zhou Y , Gwadry FG , Reinhold WC , Miller LD , Smith LH , Scherf U , et al : Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002;62: 1688-1695.

27.

Daoud SS , Munson PJ , Reinhold W , Young L , Prabhu VV , Yu Q , et al : Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 2003;63: 2782-2793.

28.

Gorgoulis VG , Vassiliou LV , Karakaidos P , Zacharatos P , Kotsinas A , Liloglou T , et al : Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434: 907-913.

29.

Halazonetis TD : Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer. DNA Repair (Amst) 2004;3: 1057-1062.

30.

Zariwala M , Liu J , Xiong Y : Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins. Oncogene 1998;17: 2787-2798.

31.

Lauper N , Beck AR , Cariou S , Richman L , Hofmann K , Reith W , et al : Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene 1998;17: 2637-2643.

32.

Geng Y , Yu Q , Whoriskey W , Dick F , Tsai KY , Ford HL , et al : Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A 2001;98: 13138-13143.

33.

Mailand N , Falck J , Lukas C , Syljuasen RG , Welcker M , Bartek J , et al : Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288: 1425-1429.

34.

Jin J , Shirogane T , Xu L , Nalepa G , Qin J , Elledge SJ , et al : SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003;17: 3062-3074.

35.

Ubeda M , Habener JF : CHOP transcription factor phosphorylation by casein kinase 2 inhibits transcriptional activation. J Biol Chem 2003;278: 40514-40520.

36.

Virolle T , Adamson ED , Baron V , Birle D , Mercola D , Mustelin T , et al : The egr-1 transcription factor directly activates PTEN during irradiation-induced signaling. Nature Cell Bio 2001;3: 1124-1128.

37.

Ragione FD , Cucciolla V , Criniti V , Indaco S , Borriello A , Zappia V : p21(Cip1) gene expression is modulated by Egr1. J Biol Chem 2003;278: 23360-23368.